Obesity and oxidative stress predict AKI after cardiac surgery. Billings FT, Pretorius M, Schildcrout JS, Mercaldo ND, Byrne JG, Ikizler TA, Brown NJ (2012) J Am Soc Nephrol 23: 1221-8 Sodium intake, ACE inhibition, and progression to ESRD. Luther JM (2012) J Am Soc Nephrol 23: 10-2 Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ (2012) J Am Soc Nephrol 23: 334-42 Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome. Hill KD, Eckhauser AW, Marney A, Brown NJ (2009) Diabetes Care 32: 857-9 Blood pressure control, drug therapy, and kidney disease. Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER, Ojo A, Sika M, Wilkening B, Toto RD, African American Study of Kidney Disease and Hypertension Study Group Investigators (2005) Hypertension 46: 44-50 ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Brown NJ, Kumar S, Painter CA, Vaughan DE (2002) Hypertension 40: 859-65 NO synthase inhibition increases aldosterone in humans. Muldowney JA, Davis SN, Vaughan DE, Brown NJ (2004) Hypertension 44: 739-45 Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition. Brown NJ, Muldowney JA, Vaughan DE (2006) Hypertension 47: 441-8 Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass. Billings FT, Balaguer JM, C Y, Wright P, Petracek MR, Byrne JG, Brown NJ, Pretorius M (2012) Clin Pharmacol Ther 91: 1065-73 Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ (2012) Crit Care Med 40: 2805-12 Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M, African American Study of Kidney Disease and Hypertension Trial Study Group (2006) Am J Kidney Dis 47: 956-64 Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ (1999) Am J Kidney Dis 34: 809-17 Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. Kaseda R, Tsuchida Y, Gamboa JL, Zhong J, Zhang L, Yang H, Dikalova A, Bian A, Davies S, Fogo AF, Linton MF, Brown NJ, Ikizler TA, Kon V (2018) Nutr Metab Cardiovasc Dis 28: 582-591 Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ (2013) Pharmacogenet Genomics 23: 470-8 Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study. Gamboa JL, Pretorius M, Sprinkel KC, Brown NJ, Ikizler TA (2015) BMC Nephrol 16: 167
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.